Aditxt Introduces AditxtScore™ for COVID-19 and Announces the Completion of Validation Studies by Stanford Blood Center
AditxtScore™ for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens
Aditxt plans to file for an Emergency Use Authorization (EUA) followed by a 510(K) application with the U.S. Food and Drug Administration by the end of the current quarter (Q3, 2020).
Additionally, Aditxt is planning its operational capabilities in anticipation of beginning pilot programs utilizing AditxtScore™ for COVID-19 in Q4, 2020, with the goal of making AditxtScore™ commercially available starting in Q1, 2021.
finance.yahoo.com/news/aditxt-introduces-aditxtscore-covid-19-120000862.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1BRFRYJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAACikHVvS8-hGnPsTNgYnMzqpJCf9wNNteEpn3akLpPYWRBhfwD6TL1Y9dpjE6jAD5e2x1h9Oturcn3SIrluCfdzDR59tmBgoF3kjOPfQBhsdhRR77DHI3feh8k54XhytdhNlAp1AQwhM7Q4_-C0pdQ-9WoHHyTvrsx29ohL3B5_9&_guc_consent_skip=1596794102
AditxtScore™ for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens
Aditxt plans to file for an Emergency Use Authorization (EUA) followed by a 510(K) application with the U.S. Food and Drug Administration by the end of the current quarter (Q3, 2020).
Additionally, Aditxt is planning its operational capabilities in anticipation of beginning pilot programs utilizing AditxtScore™ for COVID-19 in Q4, 2020, with the goal of making AditxtScore™ commercially available starting in Q1, 2021.
finance.yahoo.com/news/aditxt-introduces-aditxtscore-covid-19-120000862.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1BRFRYJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAACikHVvS8-hGnPsTNgYnMzqpJCf9wNNteEpn3akLpPYWRBhfwD6TL1Y9dpjE6jAD5e2x1h9Oturcn3SIrluCfdzDR59tmBgoF3kjOPfQBhsdhRR77DHI3feh8k54XhytdhNlAp1AQwhM7Q4_-C0pdQ-9WoHHyTvrsx29ohL3B5_9&_guc_consent_skip=1596794102
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。